## A Phase 1a, Randomized, Placebo-controlled, Single & Multiple Dose-Escalation Study to Evaluate the Safety & Tolerability of Novel Regenerative Therapeutic NNI-362 *Judith Kelleher-Andersson<sup>1</sup>, Esther Yoon<sup>2</sup>, Carol Green<sup>3</sup>, Claire Mcfarlane<sup>3</sup> and <u>R. Scott Turner</u><sup>4</sup> <sup>1</sup>Neuronascent, Inc., Clarksville, USA. <sup>2</sup>CA Clinical Trials Med Grp, Glendale, USA. <sup>3</sup>SRI, Menlo Park, USA. <sup>4</sup>Georgetown Univ., Washington DC USA.*

**BACKGROUND**: NNI-362 is a new chemical entity discovered through a phenotypic assay to identify small molecules that promote new neurons from human neural progenitor cells. Preclinical efficacy and safety studies supported a first-in-human testing in a healthy aged population. A placebo-controlled study allowed the determination of safety and tolerability, as well as secondary pharmacokinetics of two distinct NNI-362 formulations.

**OBJECTIVES**: The aim of this study was to determine the safety and tolerability of NNI-362 in a first-in-human study. **METHODS**: NNI-362 was formulated by Parexel (Glendale, CA) as an aqueous suspension or lipid suspension. Individuals were enrolled in a placebo-controlled study with a 1:3 ratio of placebo:drug. The dosing in SAD cohorts was 10, 20, 60, and 120 mg and MAD cohort at 20 mg and a SAD/MAD at 120 and 240 mg, all under fasted conditions. Direct SAD and MAD pharmacokinetics were assessed at the two highest doses. A total of 56 subjects ages 50 to 72 were randomized to intervention or placebo, with the sponsor, PI, and subjects all blinded.

				S	UBJECT DISP	OSITIO	N					
		SUB N=14 COMPLETE	N=14 SJECTS PL	SU SU SU ACEB	N=150 SUBJECTS SCREENED N=56 BJECTS RANDOMIZE N=56 UBJECTS RECEIVING BLE-BLIND MEDICATI		N=94         SCREENING FAILURES         REASONS:         Clinical Labs       32% (30)         Vital Signs       17% (16)         ECG       10% (9)         BMI       7% (7)         Backup Discharge       5% (5)         Medical History       6% (6)         Withdrawn       5% (5)         Concomit Meds       2% (2)         Physical Exam       2% (2)         Drug screen       1% (1)         Other       12% (11)					
Table 1			PI	acebo (n=1	4)		NNI-362 (n=42)					
<b>Nale</b>					5 (36%)		18 (43%)					
Age (yı	ge (yrs)				59.6 <u>+</u> 5.4		59.6 <u>+</u> 5.5					
	ole 2 Asian				_							
<b>Fable</b>	e 2	Asia	an	E A A	Black or African- merican	Wh	ite	Other	Tota			
Fable Fema	2 ale	<b>Asia</b> 10	an	E A A	Black or African- merican 5	<b>Wh</b> 1	ite 8	Other 0	Tota 33			
<b>Fable</b> Fema Male	e 2 ale	<b>Asia</b> 10 2	an		Black or African- merican 5 3	Wh 1 1	<b>ite</b> 8 6	Other 0 2	Tota         33         23			
Fable Fema Male Γotal	e 2 ale	<b>Asia</b> 10 2 12			Black or African- merican 5 3 8	Wh 18 19 34	<b>ite</b> 8 6 4	Other 0 2 2	Tota         33         23         56			
Fable Fema Male Total	e 3	Asia 10 2 12 Hisp or L	an Dani Dani		Black or African- merican 5 3 3 8 Not Hispanie Latin	Wh 13 34 C Or 0	ite 8 6 4 Un	Other 0 2 2	Tota         33         23         56			
Fema	e 3	Asia 10 2 12 Hispor L	an Dani Dani atin		Black or African- merican 5 3 3 8 Not Hispani Latin 26	Wh 1 1 3 2	ite 8 6 4 <b>Un</b>	Other 0 2 2 known	Tota         33         23         56         Total         33			
Fable   Fable   Fable   Fable   Male   Male	e 3	Asia 10 2 12 Hispor L	an bani bani bani atin 6 3		Black or African- merican 5 3 8 Not Hispani Latin 26 20	Wh 13 34 C Or 0	<b>ite</b> 8 6 4 <b>Un</b>	Other         0         2         2         2         2         1         0	Tota         33         23         56         Tota         33         23         53         23			
Fable   Fema   Male   Fema   Male   Total   Total	e 3 ale	Asia 10 2 12 Hispor L	an ban bani atin 6 3		Black or African- merican 5 3 8 Not Hispani Latin 26 20 46	Wh 1 3 3 0	<b>ite</b> 8 6 4 <b>Un</b>	Other         0         2         2         2         1         0         1         1         1         1         1         1         1	Tota         33         23         56         33         23         56			
Fable   Fema   Male   Fema   Male   Total   Male   Total	2 ale ale	Asia 10 2 12 Hispor L	an 5ani 3 3 9		Black or African- merican 5 3 3 8 Not Hispani Latin 26 20 46 46 Avg Ag	Wh 13 34 C Or 0	<b>ite</b> 8 6 4 <b>Un</b>	Other         0         2         2         2         2         1         0         1         0         1         0         1	Tota         33         23         56         33         23         56			
Fable   Fema   Male   Fema   Male   Fema   Male   Total	2 ale ale	Asia 10 2 12 Hispor L able ema	an 5ani 5ani 6 3 9		Black or African- merican 5 3 3 8 Not Hispani Latin 26 20 46 46 Avg Ag $60.1 \pm 5$	Wh 10 34 C Or 0	ite 8 6 4 <b>Un</b>	Other         0         2         2         2         1         0         1         0         1         0         1         33	Tota         33         23         56         33         23         56         33         23         56			
Fable   Fema   Male   Fema   Male   Fema   Male   Fotal   Male   Total	2 ale ale	Asia 10 2 12 Hisp or L able able	an 5ani 5ani 6 3 9 4		Black or African- merican 5 3 3 8 Not Hispani Latin 26 20 20 46 20 46 46 46 46 46 46 $59.0 \pm 5$	Wh 10 34 C Or 0	ite 8 6 4 Un	Other         0         2         2         2         1         0         1         0         1         0         1         33         23	Tota         33         23         56         Tota         33         23         56         56			

	<b>Interventional, Phase</b>	1b/2a					
Study Design	Randomized. Interver	vention Model· Parallel Assignment					
Macking	Triple (Derticipant Ca						
Masking Study Design	Randomized. Interver	tion Model: Parallel Assignment					
brady Design	Masking: Double (Par	rticipant, Investigator)					
Conditions	Parkinson's Disease (A	Age 40-72)					
Interventions:	Drug: NNI-362 oral lic	quid-gel cap Other: Placebo					
Enrollment	75 (no controls). Male	and Female					
Endpoints	<b>1º - Safety and Tolera</b>	bility, compare to baseline vMRI					
•	hippocampus	hippocampus					
	2º - OLFACT <sup>TM</sup> Test Battery or UPSIT, MDS-UPDRS,						
	MADRS-2, PDQ-39						
Arm		Intervention/Treatment					
<b>Fynarimantal</b> · N	NI_362 oral liquid	Drug. NNL-362 oral liquid 120 mg					
NNI_367 will h	e administered orally in the	Drug. NNI-362 oral liquid 240 mg					
	eatment over 6 months	Drug. 1111 502 of an inquire 2 to ing					
double-blind tre							
double-blind tre	ator:	Drug: Placebo					
double-blind tre Placebo Compara Placebo will be	ator: administered orally in the	<b>Drug</b> : Placebo Participants will receive Placebo oral					
Placebo Compara Placebo will be double-blind tre	ator: administered orally in the eatment over 6 months	Drug: Placebo Participants will receive Placebo oral liquid daily for 6 months NNI-362 in Mild to					
double-blind tre Placebo Compara Placebo will be double-blind tre <b>A Pro</b>	ator: administered orally in the eatment over 6 months oposed Study of Moderate Alzheir	Drug: Placebo Participants will receive Placebo oral liquid daily for 6 months NNI-362 in Mild to ner's Patients					
Placebo Compara Placebo will be double-blind tre <i>A Pro</i> <i>J</i> Study Type	ator: administered orally in the atment over 6 months <b>Oposed Study of</b> <b>Moderate Alzheir</b> Interventional, Phase 1	Drug: Placebo Participants will receive Placebo oral liquid daily for 6 months NNI-362 in Mild to ner's Patients b/2a					
Placebo Compara Placebo will be double-blind tre <i>A Pro</i> <i>I</i> Study Type Study Design	ator: administered orally in the atment over 6 months <b>Oposed Study of</b> <b>Moderate Alzheir</b> Interventional, Phase 1 Randomized, Interven	Drug: Placebo Participants will receive Placebo oral liquid daily for 6 months NNI-362 in Mild to ner's Patients b/2a tion Model: Parallel Assignment					
Placebo Compara Placebo will be double-blind tre <i>A Pro</i> <i>Study Type</i> Study Design Masking	ator: administered orally in the atment over 6 months <b>Oposed Study of</b> <b>Moderate Alzheir</b> Interventional, Phase 1 Randomized, Interven Triple (Participant, Car	Drug: Placebo Participants will receive Placebo oral liquid daily for 6 months NNI-362 in Mild to ner's Patients b/2a tion Model: Parallel Assignment re Provider, Investigator)					
Placebo Compara Placebo will be double-blind tre <i>A Pro</i> <i>Study Type</i> Study Design Masking Masking Conditions	ator: administered orally in the atment over 6 months <b>Oposed Study of</b> <b>Moderate Alzheir</b> Interventional, Phase 1 Randomized, Interven Triple (Participant, Car Alzheimer's disease (Ag	Drug: Placebo Participants will receive Placebo oral liquid daily for 6 months NNI-362 in Mild to ner's Patients b/2a b/2a tion Model: Parallel Assignment re Provider, Investigator) ge 60-86)					
Placebo Compara Placebo will be double-blind tre <i>A Pro</i> <i>Study Type</i> Study Design Masking Conditions Interventions:	ator: administered orally in the atment over 6 months <b>Oposed Study of</b> <b>Moderate Alzheir</b> Interventional, Phase 1 Randomized, Interven Triple (Participant, Car Alzheimer's disease (Ag Drug: NNI-362 oral liq	Drug: Placebo Participants will receive Placebo oral liquid daily for 6 months NNI-362 in Mild to ner's Patients b/2a b/2a tion Model: Parallel Assignment re Provider, Investigator) ge 60-86) uid-gel cap Other: Placebo					
Placebo Compara Placebo will be double-blind tre A Pro Study Type Study Design Masking Conditions Interventions: Enrollment	ator: administered orally in the atment over 6 months <b>Oposed Study of</b> <b>Noderate Alzheir</b> Interventional, Phase 1 Randomized, Interven Triple (Participant, Car Alzheimer's disease (Ag Drug: NNI-362 oral liq 105 (no controls), Male	Drug: Placebo Participants will receive Placebo oral liquid daily for 6 months NNI-362 in Mild to mer's Patients b/2a b/2a tion Model: Parallel Assignment re Provider, Investigator) ge 60-86) uid-gel cap Other: Placebo					
Placebo Compara Placebo will be double-blind tre A Pro A Pro Study Type Study Design Masking Masking Conditions Interventions: Enrollment Endpoints	ator: administered orally in the atment over 6 months <b>Oposed Study of</b> <b>Noderate Alzheir</b> Interventional, Phase 1 Randomized, Interven Triple (Participant, Car Alzheimer's disease (Ag Drug: NNI-362 oral liq 105 (no controls), Male 1° - Safety and Tolerab	Drug: Placebo Participants will receive Placebo oral liquid daily for 6 months NNI-362 in Mild to mer's Patients b/2a b/2a b/2a tion Model: Parallel Assignment re Provider, Investigator) ge 60-86) uid-gel cap Other: Placebo e and Female (≥50% F)					
Placebo Compara Placebo will be double-blind tre A Pro double-blind tre Study Type Study Design Masking Conditions Interventions: Enrollment Endpoints	ator: administered orally in the atment over 6 months <b>Oposed Study of</b> <b>Noderate Alzheir</b> Interventional, Phase 1 Randomized, Interven Triple (Participant, Car Alzheimer's disease (Ag Drug: NNI-362 oral liq 105 (no controls), Male hippocampus	Drug: Placebo Participants will receive Placebo oral liquid daily for 6 months NNI-362 in Mild to mer's Patients b/2a b/2a tion Model: Parallel Assignment re Provider, Investigator) ge 60-86) uid-gel cap Other: Placebo e and Female (≥50% F) oility, compare to baseline vMRI					
Placebo Compara Placebo will be double-blind tre A Pro A Pro A A Pro A A A Pro A A A Pro A A A Pro A A A Pro A A A Pro A A A A Pro A A A A A A A A A A A A A A A A A A A	ator: administered orally in the atment over 6 months <b>Oposed Study of</b> <b>Noderate Alzheir</b> Interventional, Phase 1 Randomized, Interven Triple (Participant, Car Alzheimer's disease (Ag Drug: NNI-362 oral liq 105 (no controls), Male 1° - Safety and Tolerab hippocampus 2° - OLFACT <sup>TM</sup> Test Ba	Drug: Placebo Participants will receive Placebo oral liquid daily for 6 months NNI-362 in Mild to mer's Patients b/2a tion Model: Parallel Assignment re Provider, Investigator) ge 60-86) uid-gel cap Other: Placebo e and Female (≥50% F) oility, compare to baseline vMRI					
Placebo Compara Placebo will be double-blind tre A Pro A Pro A A Pro A A A Pro A A Pro A A A Pro A A Pro A A A Pro A A A Pro A A A A A A A A A A A A A A A A A A A	ator: administered orally in the atment over 6 months <b>Dposed Study of</b> <b>Moderate Alzheir</b> Interventional, Phase 1 Randomized, Interven Triple (Participant, Car Alzheimer's disease (Ag Drug: NNI-362 oral liq 105 (no controls), Male 1° - Safety and Tolerab hippocampus 2° - OLFACT <sup>TM</sup> Test Ba State Examination (MM	Drug: Placebo         Participants will receive Placebo oral         liquid daily for 6 months         NNI-362 in Mild to         mer's Patients         b/2a         tion Model: Parallel Assignment         re Provider, Investigator)         ge 60-86)         uid-gel cap         Other: Placebo         e and Female (≥50% F)         oility, compare to baseline vMRI         attery or UPSIT, ADAS-cog., Mini Men         vISE), ADCS-ADL, Plasma-PhosphoTa					
Placebo Compars Placebo will be double-blind tre A Pro A Pro	ator: administered orally in the atment over 6 months DPOSED Study of Noderate Alzhein Interventional, Phase 1 Randomized, Interven Triple (Participant, Ca Alzheimer's disease (Ag Drug: NNI-362 oral liq 105 (no controls), Male 1° - Safety and Tolerab hippocampus 2° - OLFACT™ Test Ba State Examination (MM	Drug: Placebo         Participants will receive Placebo oral liquid daily for 6 months         NNI-362 in Mild to mer's Patients         b/2a         tion Model: Parallel Assignment         re Provider, Investigator)         ge 60-86)         uid-gel cap         Other: Placebo         e and Female (≥50% F)         oility, compare to baseline vMRI         attery or UPSIT, ADAS-cog., Mini Mer         MSE), ADCS-ADL, Plasma-PhosphoTa         ntervention/Treatment					
Placebo Compara Placebo will be double-blind tre A Pro A Pro I Study Type Study Design Masking Conditions Interventions: Enrollment Endpoints Arm	ator: administered orally in the eatment over 6 months Dposed Study of Moderate Alzheir Interventional, Phase 1 Randomized, Interven Triple (Participant, Car Alzheimer's disease (Ag Drug: NNI-362 oral liq 105 (no controls), Male 1° - Safety and Tolerab hippocampus 2° - OLFACT <sup>TM</sup> Test Ba State Examination (MM	Drug: Placebo         Participants will receive Placebo oral liquid daily for 6 months         NNI-362 in Mild to mer's Patients         b/2a         tion Model: Parallel Assignment         re Provider, Investigator)         ge 60-86)         uid-gel cap         Other: Placebo         e and Female (≥50% F)         oility, compare to baseline vMRI         attery or UPSIT, ADAS-cog., Mini Mer         MSE), ADCS-ADL, Plasma-PhosphoTa         ntervention/Treatment					
Placebo Compara Placebo will be double-blind tre A Pro A	ator: administered orally in the atment over 6 months Dposed Study of Noderate Alzheir Interventional, Phase 1 Randomized, Interven Triple (Participant, Car Alzheimer's disease (Ag Drug: NNI-362 oral liq 105 (no controls), Male 1° - Safety and Tolerab hippocampus 2° - OLFACT <sup>TM</sup> Test Ba State Examination (MM INI-362 oral liquid e administered orally in	Drug: Placebo         Participants will receive Placebo oral liquid daily for 6 months         NNI-362 in Mild to mer's Patients         b/2a         tion Model: Parallel Assignment         re Provider, Investigator)         ge 60-86)         uid-gel cap         Other: Placebo         e and Female (≥50% F)         oility, compare to baseline vMRI         attery or UPSIT, ADAS-cog., Mini Mer         MSE), ADCS-ADL, Plasma-PhosphoTa         ntervention/Treatment         Drug: NNI-362 oral liquid 120 mg         oral liquid daily for six months					
Placebo Compara Placebo will be double-blind tre A Pro A P	ator: administered orally in the satment over 6 months Dposed Study of Moderate Alzheir Interventional, Phase 1 Randomized, Interven Triple (Participant, Car Alzheimer's disease (Ag Drug: NNI-362 oral liq 105 (no controls), Male 105 (no controls), Male 1° - Safety and Tolerab hippocampus 2° - OLFACT <sup>TM</sup> Test Ba State Examination (MN I INI-362 oral liquid e administered orally in d treatment over 6	Drug: Placebo         Participants will receive Placebo oral liquid daily for 6 months         NNI-362 in Mild to         mer's Patients         b/2a         tion Model: Parallel Assignment         re Provider, Investigator)         ge 60-86)         uid-gel cap         Other: Placebo         e and Female (≥50% F)         bility, compare to baseline vMRI         attery or UPSIT, ADAS-cog., Mini Men         MSE), ADCS-ADL, Plasma-PhosphoTa         ntervention/Treatment         Drug: NNI-362 oral liquid 120 mg         oral liquid daily for six months         Drug: NNI-362 oral liquid 120 mg					

**INTRODUCTION** NNI-362, a NCE, was discovered through a phenotypic screen to identify neuron generation and neuroprotection capacity from human neural progenitors (Sumien et al., Stem Cell Res. & Ther. 12:59, 2021). NNI-362's unique MOA allosterically targets S6 kinase downstream of mTOR, that selectively stimulates translation in neural progenitor cells and promotes maturation of new neurons in aging and progressive disorders. Preclinical efficacy and safety was demonstrated prior to start of Phase1a clinical testing in an aged population (supported by NIA 1RO1 AG056561, PI: JK-A). Safety and tolerability of oral NNI-362 were the primary readouts. Secondary pharmacokinetic readouts involved two liquid formulations the first being aqueous liquid in Cohorts A-E and the second being a lipid based liquid in Cohorts F and G. Planned studies will include plasma levels of phosphoTau181 pre and post treatment in MAD Cohort 240 mg to determine potential differences with NNI-362 treatment in aged subjects (Mayo Laboratories). Further preclinical analysis of NNI-362 in an rat AAV-alpha synuclein model of Parkinson's disease showed behavioral benefit including reversal of anosmia (J Kelleher-Andersson manuscript in preparation) with immunohistochemical analysis of neuron regeneration still in progress (MOTAC, France). Long-term GLP safety in rats and dogs for 6 and 9 months, respectively, will need to be completed prior to POC trials. Proposed POC trial designs with lipid-based formulated NNI-362 for mild to moderate Alzheimer's disease and for early Parkinson's disease are provided.

## Table 5. Adverse Events

	SAD 10 mg		SAD 20 mg		SAD 60 mg		SAD 120 mg		MAD 20 mg		SAD+MAD 120 mg <sup>#</sup>		SAD+MAD 240 mg <sup>#</sup>			
AE Category (All of Mild Grade)	Placebo (n=2)	NNI-362 (n=6)	Placebo (n=2)	NNI-362 (n=6)	Placebo (n=2)	NNI-362 (n=6)	Placebo (n=2)	NNI-362 (n=6)	Placebo (n=2)	NNI-362 (n=6)	Placebo (n=2)	NNI-362 (n=6)	Placebo (n=2)	NNI-362 (n=6)	Placebo (n=14)	NNI-362
Eye Disorders <sup>1</sup>		1 (17%) <sup>UL</sup>									1 (50%)				1	1
Gastrointestinal Disorders <sup>2</sup>				1 (17%) <sup>U</sup>	2 (50%)					1 (17%)	3 (50%) <sup>U UL</sup>	1 (17%)	2 (50%)	1 (17%)	7	4
Nervous System Disorders <sup>3</sup>				1 (17%)	1 (50%)				1 (50%)	1 (17%)	2 (100%)		2 (50%)	1 (17%)	6	3
Respiratory, thoracic and mediastinal <sup>4</sup>										1 (17%) <sup>UL</sup>						1
Psychiatric <sup>5</sup>											2 (50%)			1 (17%)	2	1
Cardiac Disorders <sup>6</sup>														1 (17%) <sup>UL</sup>		1
Injury poisoning/procedural complications <sup>7</sup>												2 (33%) <sup>U U</sup>				2
Genl Disorders and Administrative sites <sup>8</sup>											1 (50%)	2 (33%) <sup>U</sup>		1 (17%)	1	3
Musculoskeletal and connective tissue <sup>9</sup>										1 (17%) <sup>U</sup>						1
															17	17
Pre-lock Definition																
U=Unrelated				1						1	1	3				
UL=Unlikely		1								1	1			1		
Possibly Treatment Related															15	9
# Oral Lipid Formulation																

months

Efficacious Dose Level <u>Potentially</u> Met at Highest Human Oral Dose (240 mg)

- Safety/Efficacy Model Male/Female Sprague-Dawley Rats

- 10 mg/kg, po (lipid formulation) showed behavioral efficacy in a rat AAV-alpha synuclein model (both motor and anosmia)

(J. Kelleher-Andersson, manuscript in preparation)

- AUC at 10 mg/kg in rat is approximately equal to the AUC at 240 mg in humans, when considering a 20-fold protein binding ratio from rat to human

- Cmax at 10 mg/kg in rats approximately 2-fold Cmax at 240 mg in humans, when considering a 20-fold protein binding ratio from rat to human

- T<sub>1/2</sub> in humans at 120 & 240 mg = 12 hrs (~6 hrs in rat)

- No safety concerns in either rat or human (no dose dependent AEs, see Table 5)

<sup>1</sup>Eye redness, conjunctivitis; <sup>1</sup>Diarrhea, constipation, nausea, emesis, borborygmi, discolored feces; <sup>3</sup>Headache, dizziness, light headed, somnolence; <sup>4</sup>Sinus discomfort; <sup>3</sup>Abnormal dreams, insomnia; <sup>8</sup>Bigeminy-asymptomatic; <sup>1</sup>Laceration, thermal burn; <sup>6</sup>Feeling calm, somber, catheter site pain, foggy; <sup>3</sup>Back pain

**Conclusions:** Oral NNI-362 appears to be safe and well tolerated at doses up to 240 mg. A maximum tolerated dose (MTD) was not reached in this healthy aged population. The liquid-lipid formulation of NNI-362 at 120 and 240 mg revealed an increased  $C_{max}$  and  $AUC_{last}$  but no increase in AEs.

These data support a proof-of-concept trial of oral NNI-362 in individuals with Alzheimer's disease and other neurodegenerative disorders of aging associated with neuronal loss.